Zeto Inc – Weekly Recap

Zeto Inc is in focus this week as the neurodiagnostics company highlighted its EEG portfolio and AI capabilities at the American Academy of Neurology Annual Meeting 2026. The company showcased Zeto ONE for hospitals, its newly FDA-cleared New Wave EEG system for clinics, and NeuroNotis, an AI-powered seizure detection reporting tool.

By presenting live demonstrations at booth #1424, Zeto is targeting both inpatient and outpatient neurology settings, signaling a push to broaden its addressable market across hospital and clinic customer segments. The combination of FDA-cleared hardware with AI-enhanced reporting workflows may strengthen product differentiation and support growth in recurring software or service revenue.

Zeto’s technology also featured prominently in a hands-on teleneurology workshop led by Massachusetts General Hospital neurologists at the same meeting. The training session used Zeto’s EEG platform in case-based demonstrations focused on practical virtual neurology workflows.

This educational exposure positions Zeto as an enabling tool for remote neurology, particularly in rural and underserved hospitals that lack on-site specialists. Increased visibility among key opinion leaders and clinicians involved in telemedicine could enhance the company’s adoption prospects in the expanding teleneurology and digital health markets.

Taken together, Zeto’s active presence on the exhibition floor and in clinical training underscores a coordinated commercial and educational push. These developments suggest a strengthening competitive position for its EEG and AI solutions, with potential to support a more durable revenue pipeline over time.